These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39423284)

  • 1. Programmable bacteria synergize with PD-1 blockade to overcome cancer cell-intrinsic immune resistance mechanisms.
    Li F; Yang Z; Savage TM; Vincent RL; de Los Santos-Alexis K; Ahn A; Rouanne M; Mariuzza DL; Danino T; Arpaia N
    Sci Immunol; 2024 Oct; 9(100):eadn9879. PubMed ID: 39423284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
    Garris CS; Arlauckas SP; Kohler RH; Trefny MP; Garren S; Piot C; Engblom C; Pfirschke C; Siwicki M; Gungabeesoon J; Freeman GJ; Warren SE; Ong S; Browning E; Twitty CG; Pierce RH; Le MH; Algazi AP; Daud AI; Pai SI; Zippelius A; Weissleder R; Pittet MJ
    Immunity; 2018 Dec; 49(6):1148-1161.e7. PubMed ID: 30552023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Wei Y; Zhang Z; Xue T; Lin Z; Chen X; Tian Y; Li Y; Jing Z; Fang W; Fang T; Li B; Chen Q; Lan T; Meng F; Zhang X; Liang X
    ACS Synth Biol; 2024 Jun; 13(6):1679-1693. PubMed ID: 38819389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment.
    Aoyama S; Nakagawa R; Nemoto S; Perez-Villarroel P; Mulé JJ; Mailloux AW
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34135102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.
    Omori R; Eguchi J; Hiroishi K; Ishii S; Hiraide A; Sakaki M; Doi H; Kajiwara A; Ito T; Kogo M; Imawari M
    Cancer Gene Ther; 2012 Sep; 19(9):637-43. PubMed ID: 22790963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.
    Torrejon DY; Abril-Rodriguez G; Champhekar AS; Tsoi J; Campbell KM; Kalbasi A; Parisi G; Zaretsky JM; Garcia-Diaz A; Puig-Saus C; Cheung-Lau G; Wohlwender T; Krystofinski P; Vega-Crespo A; Lee CM; Mascaro P; Grasso CS; Berent-Maoz B; Comin-Anduix B; Hu-Lieskovan S; Ribas A
    Cancer Discov; 2020 Aug; 10(8):1140-1157. PubMed ID: 32467343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
    Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemin blocks TIGIT/PVR interaction and induces ferroptosis to elicit synergistic effects of cancer immunotherapy.
    Zhou X; Li Y; Zhang X; Li B; Jin S; Wu M; Zhou X; Dong Q; Du J; Zhai W; Wu Y; Qiu L; Li G; Qi Y; Zhao W; Gao Y
    Sci China Life Sci; 2024 May; 67(5):996-1009. PubMed ID: 38324132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Andrographolide potentiates PD-1 blockade immunotherapy by inhibiting COX2-mediated PGE2 release.
    Liu W; Fan T; Li M; Zhang G; Guo W; Yang X; Jiang C; Li X; Xu X; Tang A; Liu K; Liu L; Kong L; Xu Q; Sun Y
    Int Immunopharmacol; 2020 Apr; 81():106206. PubMed ID: 32018066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN-γ treatment protocol for MHC-I
    Stifter K; Krieger J; Ruths L; Gout J; Mulaw M; Lechel A; Kleger A; Seufferlein T; Wagner M; Schirmbeck R
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
    Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
    Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.
    Pai CS; Huang JT; Lu X; Simons DM; Park C; Chang A; Tamaki W; Liu E; Roybal KT; Seagal J; Chen M; Hagihara K; Wei XX; DuPage M; Kwek SS; Oh DY; Daud A; Tsai KK; Wu C; Zhang L; Fasso M; Sachidanandam R; Jayaprakash A; Lin I; Casbon AJ; Kinsbury GA; Fong L
    Immunity; 2019 Feb; 50(2):477-492.e8. PubMed ID: 30737146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LAG-3 and PD-1 synergize on CD8
    Andrews LP; Butler SC; Cui J; Cillo AR; Cardello C; Liu C; Brunazzi EA; Baessler A; Xie B; Kunning SR; Ngiow SF; Huang YJ; Manne S; Sharpe AH; Delgoffe GM; Wherry EJ; Kirkwood JM; Bruno TC; Workman CJ; Vignali DAA
    Cell; 2024 Aug; 187(16):4355-4372.e22. PubMed ID: 39121848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of Interferon-
    Lv C; Yuan D; Cao Y
    J Pharmacol Exp Ther; 2021 Jan; 376(1):21-28. PubMed ID: 33158943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
    Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
    Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.